P2RY14 and gout: In a recent study, researchers designed and synthesized a novel P2Y14 receptor antagonist, which reduced the MSU-induced joint swelling and inflammatory infiltration in an acute gouty arthritis mouse model (87, 88), thus, improving the clinical value of targeted purinergic signaling in gout.